Gene therapy trial targets tough T-Cell cancers

NCT ID NCT07055477

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This early-stage trial tests a new gene therapy for certain T-cell lymphomas that have come back or not responded to treatment. The therapy uses a patient's own white blood cells, modified to attack cancer cells that carry a protein called CCR4. Up to 60 adults will receive the modified cells after chemotherapy, and researchers will monitor safety and side effects for up to 15 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CCR4 CAR T cells (a type of gene therapy using the patient's own immune cells)
What this could lead to: If it works, this could lead to a new treatment option for people with hard-to-treat T-cell lymphomas.
What could go wrong: This is an early phase 1 trial with only 60 participants, focused on safety. It may not work for everyone, and side effects could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult T-cell leukemia/lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma enteropathy-associated T-cell lymphoma hepatosplenic T-cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma monomorphic epitheliotropic intestinal T-cell lymphoma mycosis fungoides peripheral T-cell lymphoma, not otherwise specified primary cutaneous T-cell non-Hodgkin lymphoma subcutaneous panniculitis-like T-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC LARGE CELL LYMPHOMA ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA CUTANEOUS T-CELL LYMPHOMA ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA HEPATOSPLENIC T-CELL LYMPHOMA MONOMORPHIC EPITHELIALTROPIC INTESTINAL LYMPHOMA MYCOSIS FUNGOIDES PERIPHERAL T-CELL LYMPHOMA RELAPSED AND/OR REFRACTORY MATURE T CELL MALIGNANCY SUBACUTE PANNICULITIS-LIKE T-CELL LYMPHOMA

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.